Back

EPIK Biosciences advances 34 provisional patent applications for combination medicines

Verifying
  • EPIK Biosciences is advancing proprietary combination medicines for mental health, pain, and substance use disorders.
  • 34 provisional patent applications contain more than 2,700 pages of scientific and technical data.
  • EPIK plans a pre-IND FDA meeting by February 2027 and portfolio disclosure by year-end.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.